Biodistribution, pharmacokinetics and radioimmunotherapy of 188Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Biodistribution, pharmacokinetics and radioimmunotherapy of 188Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice

Published:2019-01-05 Issue:5 Volume:37 Page:961-972
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Chang Ya-Jen,Ho Chung-Li,Cheng Kai-Hung,Kuo Wan-I,Lee Wan-Chi,Lan Keng-Li,Chang Chih-Hsien

Funder

This study was supported by the grants from Ministry of Economic Affairs of Taiwan

Taipei Veterans General Hospital

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-018-00718-8.pdf

Reference53 articles.

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594. https://doi.org/10.4065/83.5.584

2. Privitera G, Luca T, Musso N, Vancheri C, Crimi N, Barresi V, Condorelli D, Castorina S (2016) In vitro antiproliferative effect of trastuzumab (Herceptin((R))) combined with cetuximab (Erbitux((R))) in a model of human non-small cell lung cancer expressing EGFR and HER2. Clin Exp Med 16(2):161–168. https://doi.org/10.1007/s10238-015-0343-8

3. Patil N, Abba M, Allgayer H (2012) Cetuximab and biomarkers in non-small-cell lung carcinoma. Biologics 6:221–231. https://doi.org/10.2147/BTT.S24217

4. Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, Vansteenkiste J, O'Byrne KJ, de Blas B, Heighway J, von Heydebreck A, Thatcher N (2014) Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer 83(2):211–218. https://doi.org/10.1016/j.lungcan.2013.11.006

5. Kim SM, Kim JS, Kim JH, Yun CO, Kim EM, Kim HK, Solca F, Choi SY, Cho BC (2010) Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. Cancer Lett 296(2):150–159. https://doi.org/10.1016/j.canlet.2010.04.006

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging;Molecular Imaging;2024-01

2. Determination of the Re-188 Calibration Number for the Capintec CRC- 25PET Dose Calibrator;Current Radiopharmaceuticals;2023-12

3. Selective Accumulation of Near Infrared-Labeled Multivalent Quinidine Copolymers in Tumors Overexpressing P-Glycoprotein: Potential for Noninvasive Diagnostic Imaging;ACS Applied Bio Materials;2023-07-27

4. Radionuclide-based theranostics — a promising strategy for lung cancer;European Journal of Nuclear Medicine and Molecular Imaging;2023-03-16

5. Radioimmunotherapy study of 131I-labeled Atezolizumab in preclinical models of colorectal cancer;EJNMMI Research;2022-10-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3